A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting now · Phase 1

Conditions studied: Metastatic Castration-Resistant Prostate Cancer

In brief

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Key facts

Study ID

NCT06879041

Run by

AstraZeneca

People needed

136

Starts

2025-03-10

Expected to finish

2029-04-16

Last updated by the study team

2026-05-12

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Research Site — Miami, Florida, United States (enrolling)
• Research Site — Boston, Massachusetts, United States (enrolling)
• Research Site — East Melbourne, Australia (enrolling)
• Research Site — Tampa, Florida, United States (enrolling)
• Research Site — Omaha, Nebraska, United States (enrolling)
• Research Site — Chicago, Illinois, United States (enrolling)
• Research Site — Portland, Oregon, United States
• Research Site — CapeTown, South Africa
• Research Site — Durban, South Africa
• Research Site — Palo Alto, California, United States
• Research Site — Pretoria, South Africa
• Research Site — San Diego, California, United States
• Research Site — Metairie, Louisiana, United States
• Research Site — Rochester, Minnesota, United States
• Research Site — New York, New York, United States
• Research Site — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.